Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Inclusion Criteria: Life expectancy > 8 weeks Albumin > 2 g/dL Histologically confirmed diagnosis of 1 of the following: solid tumor; histologic verification not required for brainstem tumors or optic pathway tumors; lymphoma; recurrent or refractory to conventional therapy OR no known effective therapy exists; bone marrow involvement allowed Performance Status: Karnofsky >= 50 % (patients > 10 years of age) OR Lansky >= 50% (patients for =< 10 years of age) Absolute neutrophil count > 1,000/mm^3 Platelet count > 100,000/mm^3 (transfusion independent) Hemoglobin > 8 g/dL (transfusion allowed) ALT < 5.0 times ULN Creatinine normal OR glomerular filtration rate >= 80 mL/min/1.73 m^2 Calcium normal (electrolyte supplements allowed) Echocardiogram and EKG normal Shortening fraction >= 27% OR ejection fraction > 50% No evidence of dyspnea at rest No exercise intolerance Pulse oximetry > 94% on room air Neurologic deficits due to CNS tumor must be relatively stable for >= 2 weeks before study entry Seizure disorder allowed provided well-controlled by non-enzyme-inducing anticonvulsants No peripheral neurotoxicity > grade 1 Sodium, potassium, and magnesium normal (electrolyte supplements allowed) At least 1 week since prior biologic agents More than 1 week since prior growth factors More than 6 months since prior allogeneic peripheral blood stem cell transplantation AND no active graft-versus-host disease More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) More than 2 weeks since prior focal radiotherapy for symptomatic metastatic sites More than 6 weeks since prior substantial bone marrow radiotherapy More than 3 months since prior craniospinal (> 24 Gy), whole pelvis, or total-body radiotherapy Recovered from all prior therapy No concurrent enzyme-inducing anticonvulsants, including, but not limited to, the following: Barbiturates; Phenytoin; Carbamazepine Exclusion Criteria: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No uncontrolled infection No history of life-threatening hypersensitivity to platinum-containing agents No prior oxaliplatin No other concurrent investigational agents No other concurrent anticancer therapy Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.